Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer

Purpose: The impact of androgen receptor (AR) activity in breast cancer biology is unclear. We characterized and tested a novel therapy to an AR-governed target in breast cancer. Experimental Design: We evaluated the expression of prototypical AR gene products human kallikrein 2 (hK2) and PSA in breast cancer models. We screened 13 well-characterized breast cancer cell lines for hK2 and PSA production upon in vitro hormone stimulation by testosterone [dihydrotestosterone (DHT)]. AR-positive lines were further evaluated by exposure to estrogen (17β-Estradiol) and the synthetic progestin D-Norgestrel. We then evaluated an anti-hK2–targeted radiotherapy platform (hu11B6), labeled with alpha (α)-particle emitting Actinium-225, to specifically treat AR-expressing breast cancer xenografts under hormone stimulation. Results: D-Norgestrel and DHT activated the AR pathway, while 17β-Estradiol did not. Competitive binding for AR protein showed similar affinity between DHT and D-Norgestrel, indicating direct AR–ligand interaction. In vivo production of hK2 was sufficient to achieve site-specific delivery of therapeutic radionuclide to tumor tissue at >20-fold over background muscle uptake; effecting long-term local tumor control. Conclusions: [225Ac]hu11B6 targeted radiotherapy was potentiated by DHT and by D-Norgestrel in murine xenograft models of breast cancer. AR activity in breast cancer correlates with kallikrein-related peptidase-2 and can be activated by D-Norgestrel, a common contraceptive, and AR induction can be harnessed for hK2-targeted breast cancer α-emitter radiotherapy.

[1]  D. Katsaros,et al.  Prostate-specific antigen in serum of women with breast cancer. , 1995, British Journal of Cancer.

[2]  G. Colditz,et al.  Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women , 2011, Clinical Cancer Research.

[3]  V. Kosma,et al.  Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women , 1999, British Journal of Cancer.

[4]  B. V. VON Schoultz,et al.  Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels. , 1989, Gynecologic and Obstetric Investigation.

[5]  R. Sitruk-Ware.  New progestagens for contraceptive use. , 2006, Human reproduction update.

[6]  H. Lilja,et al.  Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection , 2013, Thrombosis and Haemostasis.

[7]  N. Socci,et al.  Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010, Proceedings of the National Academy of Sciences.

[8]  R. Bryan,et al.  Androgen receptors in breast cancer , 1984, Cancer.

[9]  D. Tindall,et al.  Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions , 2000, British Journal of Cancer.

[10]  S. Larson,et al.  Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution. , 2015, Nuclear medicine and biology.

[11]  C. Boni,et al.  Therapeutic activity of testosterone in metastatic breast cancer. , 2014, Anticancer research.

[12]  H. Lilja,et al.  Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a 111In-radiolabelled monoclonal antibody, 11B6 , 2014, EJNMMI Research.

[13]  E. Diamandis,et al.  Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines , 2004, Breast Cancer Research and Treatment.

[14]  Kim Pettersson,et al.  Development of sensitive immunoassays for free and total human glandular kallikrein 2. , 2004, Clinical chemistry.

[15]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[16]  L. Al-Naama,et al.  Serum level of prostate-specific antigen (PSA) in women with breast cancer. , 2013, Cancer epidemiology.

[17]  A. Phillips.  The Selectivity of a New Progestin , 1990, Acta obstetricia et gynecologica Scandinavica. Supplement.

[18]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[19]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.

[20]  S. Hilsenbeck,et al.  Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells , 2010, Breast Cancer Research and Treatment.

[21]  P. Sismondi,et al.  Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue , 2005, Breast Cancer Research and Treatment.

[22]  T. Traina,et al.  Triple-Negative Breast Cancer: Role of the Androgen Receptor , 2010, Cancer journal.

[23]  A. E. Lemus,et al.  Molecular interactions of Levonorgestrel and its 5α-reduced derivative with androgen receptors in hamster flanking organs , 1995, Steroids.

[24]  S. Larson,et al.  Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis , 2016, Science Translational Medicine.

[25]  P. Sismondi,et al.  Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.

[26]  I. Tannock,et al.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[27]  Myles A Brown,et al.  Targeting the Androgen Receptor in Breast Cancer , 2015, Current Oncology Reports.

[28]  R Krattenmacher,et al.  Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. , 2000, Contraception.

[29]  P Sismondi,et al.  Serum total and free prostate-specific antigen for breast cancer diagnosis in women. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  T. Tran,et al.  Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2 , 2016, EJNMMI Research.

[31]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[32]  P. Darney.  The androgenicity of progestins. , 1995, The American journal of medicine.

[33]  S. X. Liu,et al.  Mutagenic effects of a single and an exact number of alpha particles in mammalian cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Koide,et al.  Nestorone®: a progestin with a unique pharmacological profile , 2000, Steroids.

[35]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Larson,et al.  Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer , 2018, Nature Communications.

[37]  Q. Sun,et al.  Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis , 2016, Oncotarget.

[38]  Jinbao Liu,et al.  Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide , 2019, Journal of Experimental & Clinical Cancer Research.

[39]  E. Diamandis,et al.  The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast , 2004, Breast Cancer Research and Treatment.

[40]  E. Scarpi,et al.  Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? , 2018, Front. Endocrinol..

[41]  K. Lee,et al.  Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  Paul E Swanson,et al.  Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.

[43]  M. Shehata,et al.  Androgen receptor expression in estrogen receptor-negative breast cancer , 2018 .